Last updated: September 24, 2026
Topical human thrombin is a mature hospital biologic market centered on recombinant thrombin alfa and plasma-derived human thrombin. Recothrom is the principal recombinant product, while Evithrom established the plasma-derived human thrombin segment. The market has limited branded growth, no conventional ANDA pathway, and meaningful manufacturing barriers. Public companies have not consistently disclosed standalone product revenue, so the financial outlook depends more on hospital utilization, contracting, supply continuity, and biosimilar timing than on new indications.
What is topical human thrombin and how is it used?
Topical human thrombin is a hemostatic biologic applied directly to a bleeding site during surgery. It converts fibrinogen to fibrin and supports clot formation when conventional surgical methods are inadequate or impractical.
The main product categories are:
| Product |
Active thrombin |
Source |
FDA status |
Primary commercial role |
| Recothrom |
Thrombin alfa |
Recombinant human |
FDA-approved biologic |
Standalone topical surgical hemostat |
| Evithrom |
Human thrombin |
Human plasma-derived |
FDA-approved biologic |
Standalone topical surgical hemostat |
| Vistaseal and comparable sealants |
Human thrombin plus fibrinogen |
Plasma-derived components |
FDA-approved combination products |
Fibrin sealant system, not a direct standalone thrombin substitute |
| Thrombin-JMI |
Bovine thrombin |
Bovine-derived |
FDA-approved biologic |
Non-human thrombin comparator |
Recothrom was approved in 2008. Evithrom was approved in 2007. Their clinical use includes general surgery, cardiovascular procedures, orthopedic surgery, neurosurgery, and other operations where local hemostasis is required.[1,2]
Which companies market topical human thrombin?
The market has been shaped by asset transfers and portfolio consolidation rather than by a large number of new entrants.
Recothrom ownership and commercialization
Recothrom was developed by ZymoGenetics and later commercialized through Bristol Myers Squibb. The product and related rights were subsequently transferred to The Medicines Company and later to Mallinckrodt through asset transactions.[3-5]
The commercial chain matters because topical thrombin is generally sold through hospital and surgical-product channels rather than through retail pharmacies. Product availability, group purchasing organization contracts, and operating-room formulary placement are material competitive variables.
Evithrom commercialization
Evithrom was developed and commercialized by Ethicon, a Johnson & Johnson company. The product is a plasma-derived human thrombin and competes with recombinant thrombin on source, manufacturing process, supply profile, and institutional preference.[2]
Competitive suppliers
Competition also comes from products that do not contain standalone thrombin:
- Fibrin sealants, including Vistaseal and other combination products
- Gelatin-based hemostats
- Oxidized regenerated cellulose
- Microporous polysaccharide products
- Collagen-based patches and powders
- Mechanical clips, stapling, and energy-based vessel-sealing systems
This broader competitive set limits pricing power. A hospital may evaluate topical thrombin against a full hemostasis budget rather than against another thrombin product alone.
What is the FDA regulatory status of topical human thrombin?
Recothrom and Evithrom are licensed biologics. Their regulatory pathway differs from that of conventional generic drugs.
| Regulatory issue |
Topical human thrombin position |
| Primary FDA pathway |
Biologics license application |
| Generic substitution |
No conventional ANDA substitution |
| Biosimilar pathway |
Potentially available under section 351(k) of the Public Health Service Act |
| Orange Book status |
Not the primary biologic reference source |
| Purple Book status |
Relevant biologic reference source |
| Interchangeability |
Requires a specific FDA determination; no routine pharmacy substitution framework |
| Regulatory barriers |
Manufacturing consistency, protein characterization, viral safety, potency, sterility, and delivery performance |
The Biologics Price Competition and Innovation Act created a biosimilar pathway, but a biosimilar applicant must demonstrate analytical similarity, biological activity, manufacturing comparability, and clinical or pharmacologic support appropriate to the product.[6]
Topical administration does not remove the manufacturing burden. The product must meet specifications for potency, purity, identity, sterility, stability, and formulation performance. A supplier also must establish reliable fill-finish and cold-chain processes where required.
What patents protect Recothrom and other human thrombin products?
The relevant intellectual-property estate is likely to include composition, recombinant production, purification, formulation, and use claims. Patent risk is not limited to a single active-ingredient patent.
Patent categories
| Patent category |
Relevance to topical human thrombin |
| Recombinant thrombin composition |
Covers thrombin alfa or related recombinant thrombin molecules |
| Nucleic-acid and expression technology |
Covers DNA constructs, host cells, and expression systems |
| Production and purification |
Covers activation of prothrombin and removal of impurities |
| Formulation |
Covers buffers, stabilizers, concentration, and lyophilized presentation |
| Method of use |
Covers topical application for surgical bleeding |
| Container and delivery system |
May cover vial, applicator, spray, or procedural kit configurations |
Early recombinant thrombin patents have expiration dates that generally fall in the 2020s, depending on the specific patent, priority date, patent-term adjustment, patent-term extension, and claim scope. The commercial significance of any surviving patent depends on whether it covers the active thrombin molecule, the production process, or only a narrow formulation or use.
A full current claim chart requires live review of USPTO Patent Center, FDA biologic records, assignment data, and applicable terminal-disclaimer and patent-term-adjustment records. Public product labeling confirms the biologic identity and manufacturing sponsor but does not by itself establish the complete patent estate.[1,7]
When does topical human thrombin lose exclusivity?
Topical human thrombin does not have a single exclusivity date. Its commercial protection consists of regulatory exclusivity, patents, manufacturing know-how, and hospital contracting.
Exclusivity timeline
| Event |
Recothrom |
Evithrom |
| FDA approval |
2008 |
2007 |
| New biologic exclusivity under current BPCIA framework |
Depends on reference-product designation and statutory treatment |
Depends on reference-product designation and statutory treatment |
| Likely early composition-patent expiration window |
2020s |
Patent profile differs |
| Conventional generic entry |
Not available through ANDA |
Not available through ANDA |
| Biosimilar entry |
Requires 351(k) approval |
Requires 351(k) approval |
| Practical loss of exclusivity |
Gradual, not a single date |
Gradual, not a single date |
The absence of a conventional generic filing route reduces the likelihood of an abrupt, small-molecule-style price collapse. A biosimilar could still create price pressure, but substitution would depend on FDA designation, contracting, clinical confidence, and institutional procurement policy.
Are there Paragraph IV challenges to topical human thrombin?
No conventional Paragraph IV challenge applies to Recothrom or Evithrom because Paragraph IV certifications are part of the ANDA process for small-molecule drugs. A biosimilar developer would use the BPCIA patent-dispute framework rather than submit an ANDA with a Paragraph IV certification.[6]
Potential disputes could involve:
- Patent-listing and patent-disclosure strategy
- Patent-infringement claims under 35 U.S.C. ยง 271(e)(2)
- Manufacturing-process patents
- Formulation patents
- Regulatory exclusivity
- Interchangeability and labeling issues
The practical litigation risk is therefore more likely to arise from a 351(k) application and BPCIA patent exchanges than from the classic Hatch-Waxman litigation model.
What is the financial trajectory of topical human thrombin?
Standalone revenue has been inconsistently reported. The Medicines Company disclosed Recothrom revenue in earlier annual reports, with sales generally in the high tens of millions of dollars annually rather than at blockbuster scale.[3,4]
Public financial reporting indicates a mature product profile:
| Financial factor |
Market effect |
| Hospital-only demand |
Concentrates purchasing power among institutions and group purchasing organizations |
| Surgical-volume exposure |
Revenue tracks procedure volumes and hospital capacity |
| Limited indication expansion |
Restricts organic growth |
| Mature product age |
Increases contracting and price pressure |
| Manufacturing complexity |
Supports incumbent barriers but raises supply-risk exposure |
| Product substitutability |
Limits pricing power versus fibrin sealants and mechanical hemostats |
| No conventional generic pathway |
Reduces immediate erosion risk |
| Potential biosimilar entry |
Creates medium- to long-term pricing risk |
Revenue is likely to remain stable to declining unless the supplier gains share through supply reliability, contracting, or portfolio bundling. The market is unlikely to produce material growth from new clinical demand alone. Surgical procedure recovery can support volume, but that effect is cyclical and does not change the mature competitive structure.
How strong is the patent estate for recombinant human thrombin?
The patent estate is stronger as a manufacturing barrier than as a long-term molecule monopoly.
Strengths
- Recombinant protein production requires specialized cell culture and purification capabilities.
- Potency and impurity specifications create analytical-development requirements.
- A biosimilar applicant must demonstrate similarity to a complex biologic rather than replicate a simple chemical structure.
- Manufacturing changes can affect activity, aggregation, glycosylation, and immunogenicity.
- Hospital buyers may value established supply reliability.
Weaknesses
- The product has been marketed for more than a decade.
- Core platform and composition patents may have expired or be approaching expiration.
- The active protein is a well-characterized human coagulation enzyme.
- Competing hemostats can bypass direct product substitution.
- A narrow formulation or process patent may not prevent a non-infringing biosimilar.
The overall estate is best characterized as moderate. It provides meaningful entry friction but is unlikely to support indefinite premium pricing without strong manufacturing, regulatory, or contracting advantages.
What generic and biosimilar launch scenarios exist?
Scenario 1: No approved biosimilar
The incumbent retains most of the recombinant thrombin market. Pricing remains controlled by hospital contracts, and revenue declines gradually with product maturity.
Scenario 2: One biosimilar entrant
A single biosimilar could win share through lower acquisition cost, supply guarantees, and hospital-system contracting. The incumbent may respond with rebates, bundled procurement, or service agreements.
Scenario 3: Multiple biosimilars
Multiple entrants would increase price pressure, but erosion may remain slower than for oral generics because topical thrombin is administered in operating rooms and may not receive automatic substitution.
Scenario 4: Formulation or delivery innovation
A supplier could defend share through spray delivery, improved handling, reduced preparation time, or integration into a broader surgical-hemostasis portfolio. Such improvements would compete through workflow economics rather than molecular differentiation.
What manufacturing and intellectual-property barriers affect market entry?
A new entrant must establish a validated recombinant or plasma-derived supply chain. The principal barriers include:
- Qualified cell banks or controlled plasma sourcing.
- Consistent thrombin activation and purification.
- Removal of host-cell proteins, DNA, viruses, and process contaminants.
- Potency assays that correlate with clinical performance.
- Sterile vial filling and packaging.
- Stability data for the marketed presentation.
- FDA comparability and process-validation evidence.
- Hospital-scale supply and pharmacovigilance infrastructure.
For plasma-derived products, donor screening, viral inactivation, pathogen testing, and plasma-pool controls add risk. For recombinant products, upstream and downstream process control is the central barrier.
What is the commercial outlook for topical human thrombin?
The market outlook is defensive rather than expansionary.
- Demand should track surgical procedure volumes.
- Revenue growth is likely to be limited by hospital purchasing pressure.
- Biosimilar risk is real but not immediate in the same way as ANDA-driven generic risk.
- Patent expiry alone should not cause automatic substitution.
- Supply interruptions could shift share quickly because operating rooms require dependable hemostatic products.
- Portfolio breadth may matter more than molecule-level differentiation.
The strongest commercial position belongs to a supplier with reliable manufacturing, broad hospital contracting, established surgical sales coverage, and a wider hemostasis portfolio. The weakest position belongs to a single-product supplier exposed to one manufacturing site or one major hospital contract.
Key Takeaways
- Recothrom and Evithrom are the principal standalone human thrombin products.
- Recothrom is recombinant thrombin alfa; Evithrom is plasma-derived human thrombin.
- These products are biologics and do not face conventional ANDA or Paragraph IV challenges.
- A future entrant would use the 351(k) biosimilar pathway or another biologic approval route.
- The patent estate is more important for manufacturing and formulation protection than for a permanent composition monopoly.
- Public financial disclosures indicate a mature, hospital-based market with sales generally in the high tens of millions for historically reported Recothrom periods.
- Pricing is constrained by hospital contracting and alternative hemostatic products.
- Long-term erosion is likely to be gradual unless a biosimilar achieves broad institutional adoption.
FAQs About Topical Human Thrombin
Is Recothrom a biosimilar or a generic?
No. Recothrom is an original biologic containing recombinant human thrombin alfa. A future competitor would generally pursue a biosimilar or standalone biologic approval rather than an ANDA.
Is topical human thrombin listed in the Orange Book?
Biologic reference information is primarily evaluated through FDA biologic records and the Purple Book rather than through the conventional Orange Book framework used for small-molecule drugs.
Can hospitals automatically substitute a biosimilar thrombin product?
Not necessarily. Automatic substitution would depend on FDA interchangeability status, state law, institutional policy, and procurement rules.
Does human thrombin compete directly with fibrin sealants?
Only partly. Fibrin sealants contain thrombin with fibrinogen and are used as combination products. They compete for surgical-hemostasis budgets but are not identical standalone products.
What is the largest risk to future thrombin revenue?
The largest commercial risks are hospital price contracting, substitution by other hemostatic technologies, supply interruptions, and eventual biosimilar competition.
References
- U.S. Food and Drug Administration. (2008). Recothrom thrombin topical recombinant prescribing information.
- U.S. Food and Drug Administration. (2007). Evithrom thrombin topical human prescribing information.
- The Medicines Company. (2014). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- The Medicines Company. (2015). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- Mallinckrodt plc. (2016). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
- U.S. Food and Drug Administration. (2023). Biosimilar and interchangeable biosimilar products.
- U.S. Patent and Trademark Office. (2024). Patent Center and patent-term information resources.
